AGAP2 and non-small cell lung carcinoma: Multivariate analysis of the four prognostic factors confirmed that HR for AGAP2-AS1 expression is 3.422 (95% confidence interval (CI): 1.851–6.327) of progression-free survival, indicating that AGAP2-AS1 expression may serve as a potential independent prognostic value in NSCLC (Table 2).